Atossa Therapeutics CEO Dr. Steven Quay to Participate in ARDD 2026 Panel on Clinical Trials and Regulatory Pathways for Diseases of Aging
Atossa Therapeutics Inc ATOS
$1.90
▼ -7.32%
($-0.15)
⬇️ Below Yest. Low
🎈 Low Float
Open
$2.06
Prev Close
$2.05
Day Range
$1.89 – $2.07
52W Range
$1.70 – $19.35
Market Cap
$18.96M
Beta
1.39
EPS (TTM)
$-4.34
📋 Company Profile
| Industry | Biotechnology |
| Country | US |
| Exchange | NASDAQ NMS - GLOBAL MARKET |
| Currency | USD |
| IPO Date | 2012-11-08 |
| Shares Out. | 9,970,000 |
| Website | atossatherapeutics.com/ ↗ |
| Phone | 12065880256 |
| Employees | 14 |
| Revenue | $0 |
| Gross Profit | $0 |
| Net Income | -$8.5M |
| Free Cash Flow | -$35.8M |
| Total Assets | $32.3M |
| Total Liabilities | $5.5M |
| Equity | $26.8M |
About Atossa Therapeutics Inc
Atossa Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the development of proprietary medicines for oncology, with a focus on breast cancer and related conditions. The company's lead product candidate, oral (Z)-endoxifen, is a selective estrogen receptor modulator and degrader (SERM/SERD) in Phase 2 clinical development, being evaluated for the treatment and prevention of breast cancer and other indications.
Atossa Therapeutics Inc is a publicly traded company under the ticker symbol ATOS on the NASDAQ NMS - GLOBAL MARKET, operating in the Biotechnology industry. Quotes and metrics shown here are sourced from public market data and refreshed regularly.
📊 Analyst Ratings
8 analysts (2026-09-01)